Search Results - "Seymour, K. L."

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 by Chu, Q. S.-C., Nielsen, T.O., Alcindor, T., Gupta, A., Endo, M., Goytain, A., Xu, H., Verma, S., Tozer, R., Knowling, M., Bramwell, V.B., Powers, J., Seymour, L.K., Eisenhauer, E.A.

“…Fusion transcription genes/oncoproteins generated from translocation-associated sarcomas modulate gene transcription via histone deacetylase-containing…”
Get full text

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer by Burdett, Sarah, Pignon, Jean Pierre, Tierney, Jayne, Tribodet, Helene, Stewart, Lesley, Le Pechoux, Cecile, Aupérin, Anne, Le Chevalier, Thierry, Stephens, Richard J, Arriagada, Rodrigo, Higgins, Julian P T, Johnson, David H, Van Meerbeeck, Jan, Parmar, Mahesh K B, Souhami, Robert L, Bergman, Bengt, Douillard, Jean-Yves, Dunant, Ariane, Endo, Chiaki, Girling, David, Kato, Harubumi, Keller, Steven M, Kimura, Hideki, Knuuttila, Aija, Kodama, Ken, Komaki, Ritsuko, Kris, Mark G, Lad, Thomas, Mineo, Tommaso, Piantadosi, Steven, Rosell, Rafael, Scagliotti, Giorgio, Seymour, Lesley K, Shepherd, Frances A, Sylvester, Richard, Tada, Hirohito, Tanaka, Fumihiro, Torri, Valter, Waller, David, Liang, Ying

“…To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients…”
Get more information

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 by Gelmon, K. A., Stewart, D., Chi, K. N., Chia, S., Cripps, C., Huan, S., Janke, S., Ayers, D., Fry, D., Shabbits, J. A., Walsh, W., McIntosh, L., Seymour, L. K.

“…Background: AMD473 (previously ZD0473) is a new-generation platinum compound with activity against a wide range of human tumour cell lines and xenografts,…”
Get full text

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors : IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group by GOSS, G, SIU, L. L, DROLET, D. W, RUSK, J, SEYMOUR, L. K, GAUTHIER, I, CHEN, E. X, OZA, A. M, GOEL, R, MAROUN, J, POWERS, J, WALSH, W, MACLEAN, M

“…To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile, dose-limiting toxicities (DLTs),…”
Get full text

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129 by Gelmon, K. A., Vandenberg, T. A., Panasci, L., Norris, B., Crump, M., Douglas, L., Walsh, W., Matthews, S. J., Seymour, L. K.

“…Background: ZD0473 is a new generation platinum compound with activity against a wide range of human tumor cell lines and xenografts, including carboplatin-…”
Get full text

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group by Goss, G, Hirte, H, Miller, Jr, W H, Lorimer, I A J, Stewart, D, Batist, G, Parolin, D A E, Hanna, P, Stafford, S, Friedmann, J, Walsh, W, Mathews, S, Douglas, L, Seymour, L K

“…To define the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), the biological active (BA) dose and the pharmacokinetics (PK) of the epidermal…”
Get full text

Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents by Seymour, L K

“…A number of cancer chemotherapeutics targeting the epidermal growth factor receptor (EGFR) are in development. These compounds were designed to either bind to…”
Get more information

Tracking the evolution of the elusive Andean mountain cat (Oreailurus jacobita) from mitochondrial DNA by Johnson, W E, Culver, M, Iriarte, J A, Eizirik, E, Seymour, K L, O'Brien, S J

“…Rarely observed in the wild, the existence of the Andean mountain cat (Oreailurus jacobita) has been established based on only 3 skulls and 14 museum skins…”
Get full text

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease by SEYMOUR, L. K, DANSEY, R. D, BEZWODA, W. R

“…A simplified schedule of high-dose chemotherapy (HDC) consisting of melphalan (140 mg m-2) plus VP16 (2.5 g m-2) given over 12-18 h together with autologous…”
Get full text

Pre-Late Wisconsinan Pleistocene biota from southeastern Michigan, U.S.A by Karrow, P.F., Seymour, K.L., Miller, B.B., Mirecki, J.E.

“…Fossiliferous sediments underlie the Late Wisconsinan Mill Creek and Fisher Road tills at the Mill Creek site northwest of Port Huron, Michigan. Fragmentary…”
Get full text

Disparate phylogeographic patterns of molecular genetic variation in four closely related South American small cat species by Johnson, Warren E., Slattery, Jill Pecon, Eizirik, Eduardo, Kim, Jae-Heup, Menotti Raymond, Marilyn, Bonacic, Cristian, Cambre, Richard, Crawshaw, Peter, Nunes, Adauto, Seuánez, Héctor N., Martins Moreira, Miguel Angelo, Seymour, Kevin L., Simon, Faiçal, Swanson, William, O'Brien, Stephen J.

“…Tissue specimens from four species of Neotropical small cats (Oncifelis geoffroyi, N = 38; O. guigna, N = 6; Leopardus tigrinus, N = 32; Lynchailurus colocolo,…”
Get full text

Prognostic factors in chronic myeloid leukaemia : importance of staging or disease biology by ARIAD, S, SEYMOUR, L. K, MACPHAIL, A. P, WEAVING, E. A, BEZWODA, W. R

“…The presenting clinical, haematological and cytogenetic features of 215 patients with a haematological diagnosis of chronic myeloid leukaemia (CML) were…”
Get full text

1758PDComplementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG) by Wells, J C, Sidhu, A, Ding, K, Heng, D Y C, Shepherd, F, Ellis, P M, Bradbury, P A, Jonker, D J, Moore, M, Siu, L L, Gelmon, K A, Karapetis, C, Shapiro, J, Nott, L, O’Callaghan, C J, Parulekar, W R, Seymour, L K, Smoragiewicz, M, Monzon, J G

“…Abstract Background CMs are products used concurrently with conventional medicine, including natural products and homeopathy. CM use is prevalent amongst…”
Get full text

474PPharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy by Hao, D, Ellis, P M, Laurie, S A, Juergens, R A, Mates, M, Bradbury, P A, Tsao, M, Tehfe, M, Kollmannsberger, C K, Goffin, J R, Wheatley-Price, P, Hilton, J, Robinson, A G, Brown-Walker, P, Tu, D, Smoragiewicz, M, Seymour, L K

“…Abstract Background In this phase Ib multicenter study, we sought to characterize the PK, safety and tolerability of durvalumab (D), an anti-PD-L1 antibody, ±…”
Get full text

LBA51CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) by Hotte, S J, Winquist, E, Chi, K N, Ellard, S L, Sridhar, S, Emmenegger, U, Salim, M, Iqbal, N N, Canil, C, Kollmannsberger, C K, Hansen, A R, Lalani, A-K A, Gingerich, J, Finch, D, Cabanero, M, Wyatt, A W, Tu, D, Vera-Badillo, F, Seymour, L K, Smoragiewicz, M

“…Abstract Background PD-L1 is overexpressed by dendritic cells of mCRPC patients (pts) progressing on androgen receptor antagonist therapy. Anti-PD-1 agents…”
Get full text

In the News by Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., Johnson, B. T., Rovero, F., Rathbun, G. B., Perkin, A., Jones, T., Ribble, D. O., Leonard, C., Mwakisoma, R. R., Spolyar, D., Freese, K., Gondolo, P., Simmons, N. B., Seymour, K. L., Habersetzer, J., Gunnell, G. F., Perrichot, V., Marion, L., Neraudeau, D., Vullo, R., Tafforeau, P., Fargione, J., Hill, J., Tilman, D., Polasky, S., Hawthorne, P., Christner, B. C., Morris, C. E., Foreman, C. M., Cai, R., Sands, D. C.

Get full text

Oreailurus jacobita by Yensen, E, Seymour, K L

Get full text

Panthera onca by Seymour, Kevin L.

Get full text

Tracking the evolution of the elusive Andean mountain cat (Oreailurus jacobita from mitochondrial DNA by Johnson, WE, Culver, M, Iriarte, JA, Eizirik, E, Seymour, KL, O'Brien, SJ

“…Rarely observed in the wild, the existence of the Andean mountain cat (Oreailurus jacobita has been established based on only 3 skulls and 14 museum skins. The…”
Get full text